KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
      QxMD      Google Scholar   
Citation:
Clin Cancer Res vol 15 (23) 7322-7329
Year:
2009
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
527   620  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, U10 CA032291, U10 CA046282-15, CA33601, U10 CA071323, R01 CA118553, K07 CA122826-01A1, U10 CA077658, U10 CA032291-22, R01 CA118553-02, U10 CA045564, U10 CA035279, U10 CA045808, U10 CA031946, U10 CA033601, R01 CA118553-01A2, U10 CA045389, U10 CA077597, UL1 RR025741, U10 CA035421, U10 CA114558, K07 CA122826-03, R01 CA118553-03, U10 CA045418, K07 CA122826, U10 CA077440, U10 CA180850, U10 CA041287, U10 CA047559, U10 CA077651, U10 CA031946-24, U10 CA033601-25, U10 CA038926-18, U10 CA023318-27, U10 CA038926, U10 CA023318, U10 CA074811, U10 CA035415-20, P50 CA127003-01, K07 CA122826-02, U10 CA047642, P50 CA127003, CA31946, U10 CA003927, U10 CA077651-07  
Corr. Author:
 
Authors:
                             
Networks:
 
Study
CALGB-150705
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-89803
Phases:
N/A, 3
Keywords:
colorectal cancer, K-RAS, predictive, prognostic, response